RxDoctor Payments Data

Koshy Oommen, MD

Internal Medicine · Greenwood, INNPI 1497844278

Payments from drug & device makers

$8,287in general payments, 2019–2025

Across 532 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$907
  • AstraZeneca$862
  • Lilly USA, LLC$820
  • Corcept Therapeutics$412
  • Amgen$356
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$8,250100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,287 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$251,685
Medicare patients
320
Services billed
3,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide192$252,216
MounjaroTirzepatide117$140,325
EliquisApixaban85$90,571
JardianceEmpagliflozin42$47,714
FarxigaDapagliflozin Propanediol41$38,050
JanuviaSitagliptin Phosphate32$32,305
MyrbetriqMirabegron33$25,863
XareltoRivaroxaban19$25,784
RybelsusSemaglutide19$23,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,759
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$13,698
Tresiba Flextouch U-200Insulin Degludec13$12,416
Breo ElliptaFluticasone/Vilanterol22$9,002
Tresiba Flextouch U-100Insulin Degludec11$6,365
Atorvastatin Calcium470$5,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,740$275,826211 claims
Lilly USA, LLCMounjaro$820$140,325117 claims
PfizerEliquis$216$90,57185 claims
Boehringer IngelheimJardiance$270$47,71442 claims
AstraZenecaFarxiga$862$38,05041 claims
MerckJanuvia$144$32,30532 claims
GSKTrelegy Ellipta, Breo Ellipta$289$31,76146 claims
Astellas Pharma US IncMyrbetriq$13$25,86333 claims
Johnson & JohnsonXarelto$109$25,78419 claims
AbbVieSynthroid$907$2,08732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →